Tumor burden-guided dosing of obe-cel in patients with R/R B-cell ALL: Results from the FELIX trial

We summarize results from the phase Ib/II FELIX trial of tumor burden-guided administration of...

SOHO 2024 live congress feed

Stay up to date with the latest developments in ALL from the SOHO 2024 Annual Meeting with our live social media coverage.

Brexu-cel for patients with R/R B-ALL: 4-year follow-up from the ZUMA-3 trial

We summarize long-term survival outcomes with a 4-year follow-up from the ZUMA-3 trial of brexu-cel for patients with R/R...

JZP458 in ALL/LBL: Post hoc analysis from AALL1931 trial

We summarize results of the post hoc analysis from the AALL1931 trial assessing the safety of JZP458 in children and adult patients with...

Revumenib receives FDA approval for adult and pediatric patients aged ≥1 year with R/R ALL and a KMT2A translocation

On November 15, 2024, the FDA approved revumenib for the treatment of adult and...

Inotuzumab ozogamicin plus low-intensity chemotherapy in older patients with newly diagnosed CD22+ Ph− B-ALL: Results from the EWALL-INO trial

We summarize results from the EWALL-INO trial, a...

Long-term survival outcomes in patients with ALL who were alive and disease-free 2 years after allo-HSCT

We summarize results from a retrospective analysis assessing long-term survival in patients...

FDA grants marketing approval for obecabtagene autoleucel for adult patients with R/R B-ALL

Following positive response data from the phase Ib/II FELIX study, obecabtagene autoleucel receives...

FDA grants marketing approval for obecabtagene autoleucel for adult patients with R/R B-ALL

Following positive response data from the phase Ib/II FELIX study, obecabtagene autoleucel receives...

Anti-CD19 CAR T-cell therapy with shRNA IL-6 gene silencing element for patients with R/R B-ALL

We summarize a post hoc analysis comparing data from a phase I/II trial of ssCAR T-cells and a phase...

Comparison of outcomes of patients aged ≥26 years with R/R B-ALL in ZUMA-3 and historical trials

We summarize results from the ZUMA-3 trial of brexu-cel vs historical SoC therapy in patients aged ≥26...

Inotuzumab ozogamicin in combination with dexamethasone as induction for older patients with B-ALL: Results from the INITIAL-1 study

We summarize results from the INITIAL-1 trial of inotuzumab...

Addition of venetoclax to hyper-CVAD-nelarabine-pegAsp for T-ALL/LBL: 2-year follow-up from the phase II trial

We summarize long-term results published in Leukemia by Ravandi et al that assessed the...

The 2023 JSH practical guidelines for hematological malignancies: ALL

We summarize recommendations from the 2023 JSH practical guidelines for hematological malignancies, including for the treatment of...

Factors influencing survival following first relapse in ALL: A Children’s Oncology Group study

We summarize the results from a large retrospective study investigating additional risk factors that may...

DELPHINUS: Daratumumab plus chemotherapy in pediatric patients with R/R ALL or LL

We summarize results from the phase II DELPHINUS trial assessing daratumumab plus backbone chemotherapy in pediatric...